Higher doses of intravenous rifampicin may improve outcomes in tuberculous meningitis but are impractical in high-burden settings. We hypothesized that plasma rifampicin exposures would be similar between oral dosing of 35 mg/kg of body weight and intravenous dosing of 20 mg/kg, which has been proposed for efficacy trials in tuberculous meningitis.
No takes yet. Share an insight, caveat, or question.
Wasserman et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: